Type 2 Diabetes: SGLT2i-Associated Genitourinary Infections and Lower Urinary Tract Dysfunction

Type 2 diabetes (T2D) is considered an epidemic in the United States and presents a major economic strain on patients and the health care system. Patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2i) for T2D management are predisposed to genitourinary infections and Fournier gangrene. This article provides details on an overview of SGLT2i, including their use in the treatment of T2D, associated genitourinary infections and the effect of T2D on lower urinary tract (LUT) dysfunction. Nonpharmacologic and pharmacologic management strategies are also included to manage genitourinary side effects of SGLT2i and optimize bladder function and possibly minimize LUT dysfunction. •Type 2 diabetes mellitus (T2D) is a significant chronic health concern worldwide and is associated with various complications, including macrovascular and microvascular complications, and death.•It is well known that T2D is associated with upper urinary tract and renal dysfunction, but patients with T2D also experience lower urinary tract (LUT) symptoms, which can be early signs of bladder dysfunction.•Sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with genitourinary side effects of urinary tract infections, mycotic genital infections, and possible Fournier gangrene.•Enhancing knowledge on pathophysiology and management of T2D to minimize genitourinary side effects of SGLT2 inhibitors and LUT dysfunction is crucial to provide comprehensive quality care to patients with T2D.